Dulaglutide combined with alfacalcitol for patients with type 2 diabetes mellitus complicated with osteoporosis
Objective To explore the curative effect of dulaglutide combined with alfacalcitol for patients with type 2 diabetes mellitus complicated with osteoporosis.Methods A total of 107 patients with type 2 diabetes mellitus complicated with osteoporosis admitted to Department of Endocrinology,Shanxian Central Hospital from January 2022 to June 2023 were selected for the randomized controlled trial,and were divided into an observation group(54 cases)and a control group(53 cases)by the random number table method.In the control group,there were 26 males and 27 females;they were(66.57±8.91)years old;the diabetes course was(8.87±1.56)years;their body mass index was(22.34±1.59)kg/m2.In the observation group,there 25 males and 29 females;they were(65.23±8.81)years old;the diabetes course was(8.53± 1.21)years;their body index was(22.52±1.68)kg/m2.Both groups were given metformin for routine hypoglycemia;in addition,the control group orally took alfacalcitol,and the observation group took dulaglutide and alfacalcitol.The clinical efficacies,changes of blood glucose[fasting plasma glucose(FPG),2 hours plasma glucose(2hPG),and glycosylated hemoglobin(HbA1c)]and bone metabolism indicators,and incidences of adverse reactions in both groups were observed.t and x2 tests were observed.Results The total effective rate of the observation group was higher than that of the control group[96.30％(52/54)vs.84.91％(45/53)],with a statistical difference(x2=4.096,P=0.043).After the treatment,the levels of FPG,2 h PBG,and HbA1c in the observation group were lower than those in the control group[(6.41±1.36)mmol/L vs.(7.27±1.18)mmol/L,(9.63± 2.21)mmol/L vs.(11.57±2.43)mmol/L,and(5.58±1.29)％vs.(7.21±1.67)％],with statistical differences(t=-3.491,-4.322,and-5.656;all P＜0.05).After the treatment,the serum calcium(Ca)concentration and bone specific alkaline phosphatase(BALP)level in the observation group were higher than those in the control group[(2.67±0.45)mmol/L vs.(2.43±0.48)mmol/L and(19.38± 3.31)U/L vs.(17.27±3.19)U/L];the alkaline phosphatase(ALP)level in the observation group was lower than that in the control group[(32.75±9.34)U/L vs.(36.82±9.49)U/L];there were statistical differences(t=2.669,3.357,and-2.225;all P＜0.05).There was no statistical differences in the incidence of adverse reactions between the observation group and the control group[5.56％(3/54)vs.9.43％(5/53);x2=0.582;P=0.446].Conclusion Duloglucoptide combined with alfacalcitol is effective in the treatment of patients with type 2 diabetes mellitus complicated with osteoporosis,and can effectively control their blood glucose and improve their osteoporosis,and is safe.
Type 2 diabetes mellitusOsteoporosisDulaglutideAlfacalcitol
万方数据
维普
